MerLion Pharmaceuticals Pte Ltd
http://www.merlionpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MerLion Pharmaceuticals Pte Ltd
Finance Watch: The Growing $100m-Plus VC Club
Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome
An FDA advisory committee review of quinolone antibiotic safety focused on a very old safety issue – but points to a new era in antibiotic development, and restricted use models.
MerLion Preps Finafloxacin For Phase III As Advantages Confirmed
Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET
-
Molecular Diversity
- Natural Products
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice